Trials / Completed
CompletedNCT03620370
Normobaric Hyperoxia Combined With Reperfusion for Acute Ischemic Stroke
The Safety and Efficacy of Normobaric Hyperoxia Combined With Reperfusion for Acute Ischemic Stroke：A Randomized, Controlled Pilot Study
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 86 (actual)
- Sponsor
- Capital Medical University · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
NBO is a nonpharmacological measure of neuroprotection. The purpose of our study is to evaluate the safety and efficiency of NBO（Normobaric hyperoxia) in the acute ischemic stroke patients who received endovascular treatment. Looking for more clinical evidence for the ischemic stroke patients who will be treated with NBO in the future.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Normobaric oxygen therapy | In this study, it is simple to administer via oxygen storage facemask at flow rates of 10 L/min for 4 hours. This therapy start should in Pre-hospital or emergency room as early as possible after diagnosed ischemic stroke and uninterrupted during other treatments including mechanical thrombolytic therapy and standard clinical treatment. |
Timeline
- Start date
- 2018-08-12
- Primary completion
- 2019-07-21
- Completion
- 2019-10-19
- First posted
- 2018-08-08
- Last updated
- 2023-07-19
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03620370. Inclusion in this directory is not an endorsement.